Abstract: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Abstract: The invention relates to the use of Alum for the preparation of a drug for enhancing an antigen-specific type 1 immune response against an antigen in the presence of a type 1 inducing adjuvant.

Abstract: Disclosed is a Hepatitis C virus (HCV) vaccine comprising at least two epitopes, each from a different hotspot epitope, wherein a hotspot epitope is defined as an epitope containing peptide selected from the group consisting of KFPGGGQIVGGVYLLPRRGPRLGVRATRK, GYKVLVLNPSVAAT, AYAAQGYKVLVLNPSVAAT, DLMGYIP(A/L)VGAPL, GEVQVVSTATQSFLATCINGVCWTV, HMWNFISGIQYLAGLSTLPGNPA, VDYPYRLWHYPCT(V/I)N(F/Y)TIFK(V/I)RMYVGGVEHRL, AAWYELTPAETTVRLR, GQGWRLLAPITAYSQQTRGLLGCIV, IGLGKVLVDILAGYGAGVAGALVAFK, FTDNSSPPAVPQTFQV, LEDRDRSELSPLLLSTTEW, YLVAYQATVCARAQAPPPSWD, MSTNPKPQRKTKRNTNR, LINTNGSWHINRTALNCNDSL, TTILGIGTVLDQAET, FDS(S/V)VLCECYDAG(A/C)AWYE, ARLIVFPDLGVRVCEKMALY, AFCSAMYVGDLCGSV, GVLFGLAYFSMVGNW, VVCCSMSYTWTGALITPC, TRVPYFVRAQGLIRA and TTLLFNILGGWVAAQ.

Abstract: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.

Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZXZN-XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.

Abstract: Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a tumour antigen. The adjuvant is capable of increasing the binding of the peptide to the cells of the individual to be treated or of increasing the entry of the peptide into the cells and strengthening the immunomodulatory activity of the peptide. Preferred adjuvants are basic polyamino acids such as polyarginine or polylysine, optionally conjugated with a cellular ligand such as a carbohydrate group or transferrin. The composition is particularly intended for use as a vaccine, e.g. as a tumour vaccine.

Abstract: The inventions discloses a pharmaceutical composition comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, x is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independantly one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: A vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants is present in the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions. Preferably, it contains substances capable of making the vaccine isotonic, particularly sorbitol.

Abstract: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament for treating or preventing inflammation and for the preparation of a medicament with reduced inflammatory potential.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Abstract: The invention relates to a composition comprising

Abstract: The inventions discloses a pharmaceutical composition comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

Abstract: Pharmaceutical preparation comprising a peptide of the formula

Abstract: The invention disclose a pharmaceutical composition comprising an antigen, an immunogenic CpG-ODN and a polycationic polymer.

Abstract: Tumor vaccine and process for the preparation thereof. The tumor vaccine contains tumor cells at least some of which contain at least one MHC-I-haplotype of the patient on the cell surface, and which are charged with one or more peptides binding to the MHC-I molecule in such a way that the tumor cells are recognized as foreign by the patient's immune system in context with the peptides and trigger a cellular immune response. The charging is carried out in the presence of a polycation such as polylysine.

Abstract: Process and medium for the transfection of higher eukaryotic cells with DNA/polycation complexes, wherein a medium is used which contains ethyleneglycol and/or glycerol. The medium may also contain a substance which prevents the acidification of the endosomes, and/or a lower alcohol such as ethanol. The process is particularly suitable for the transfection of primary cells such as fibroblasts. Stably transformed cells can be obtained thereby, e.g. tumour cells for use as tumour vaccines.